α-MSH modulates experimental inflammatory bowel disease

Peptides

Volumn 18, Issue 3, 1997, Pages 381-385

  Rajora, Nilum ^a   Boccoli, Giovanni ^b   Catania, Anna ^b   Lipton, J M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

MSH; Antiinflammatory; Colitis; Inflammatory bowel disease; Mice; Nitric oxide; peptide; TNF

Indexed keywords

ALPHA INTERMEDIN; CYTOKINE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENTERITIS; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ALPHA-MSH; ANIMALS; CONCANAVALIN A; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL HEMORRHAGE; INFLAMMATORY BOWEL DISEASES; INTESTINE, LARGE; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; OCCULT BLOOD; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

ANIMALIA; MURINAE;

EID: 0042399698     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00345-2     Document Type: Article

References (32)

1. Airaghi L., Lettino M., Manfredi M. G., Lipton J. M., Catania A. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am. Heart. J. 130:1995;204-211.
2. Beil W. J., Weller P. F., Peppercorn M. A., Galli S. J., Dvorak A. M. Ultrastructural immunogold localization of subcellular sites of TNFα in colonic Crohn's disease. J. Leukocyte. Biol. 58:1995;284-298.
3. Breese E. J., Michie C. A., Nicholls S. W., Murch S. H., Williams C. B., Domizio P., Walker-Smith J. A., MacDonald T. T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 106:1994;1455-1466.
4. Catania A., Gerloni V., Procaccia S., Airaghi, Manfredi M. G., Lomater C., Grossi L., Lipton J. M. The anti-cytokine neuropeptide α -MSH in synovial fluid of patients with rheumatic diseases: Comparisons with other anti-cytokine molecules. NeuroImmunoModulation. 1:1994;321-328.
5. Catania A., Lipton J. M. The neuropeptide alpha-melanocyte-stimulating hormone: A key component of neuroimmunomodulation. NeuroImmunoModulation. 1:1994;93-99.
6. Catania A., Lipton J. M. α -Melanocyte stimulating hormone in the modulation of host reactions. Endocrine Rev. 14:1993;564-576.
7. Catania A., Manfredi M. G., Airaghi L., Ceriani G., Gandino A., Lipton J. M. Cytokine antagonists in infectious and inflammatory disorders. Ann. NY Acad. Sci. 741:1994;149-161.
8. Catania A., Suffredini A. F., Lipton J. M. Endotoxin causes α -MSH release in normal human subjects. NeuroImmunoModulation. 2:1995;258-262.
9. Catania A., Rajora N., Capsoni F., Minonzio F., Star R. A., Lipton J. M. The neuropeptide α -MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides. 17:1996;675-679.
10. Ceriani G., Diaz J., Murphree S., Catania A., Lipton J. M. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. NeuroImmunoModulation. 1:1994;28-32.
11. Chiao H., Foster S., Thomas R., Lipton J., Star R. A. α -MSH reduces endotoxin-induced liver inflammation. J. Clin. Invest. 97:1996;2038-2044.
12. Funakoshi K., Sugimura K., Sasakawa T., Bannai H., Anezaki K., Ishizuka K., Yoshida K., Narisawa R., Asakura H. Study of cytokines in ulcerative colitis. J. Gastroenterol. 30:((Suppl 8)):1995;61-63.
13. Glickman R. M. Inflammatory bowel disease. In: Harrison's principles of internal medicine, 11th Ed. Braunwald E., Isselbacher K. J., Petersdorf R. G., Wilson J. D., Martin J. B., Fauci A. S. 1987;1277-1290 McGraw-Hill, New York.
14. Grabbe S., Bhardwaj R. S., Mahnke K., Simon M. M., Schwarz T., Luger T. A. α -melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J. Immunol. 156:1996;473-478.
15. Huh S.-K., Lipton J. M., Batjer H. H. The protective effects of α -melanocyte stimulating hormone on canine brainstem ischemia. J. Neurosurg. 40:1997;132-139.
16. Kusugami K., Fukatsu A., Tanimoto M., Shinoda M., Haruta J., Kuroiwa A., Ina K., Kanayama K., Ando T., Matsuura T. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Digest. Dis. Sci. 40:1995;949-959.
17. Lipton, J. M.; Catania, A. P. Antiinflammatory influence of the neuroimmunomodulator α -MSH. Immunol. Today (in press).
18. Lipton, J. M.; Catania, A.; Rajora, N.; Ceriani, G.; Star, R. A.; Boccoli, G. Modulation of inflammatory effects of cytokines by the neuropeptide α -MSH. In: Proinflammatory and antiinflammatory peptides, lung biology in health and disease. New York: Marcel Dekker; (in press).
19. Lipton J. M., Ceriani G., Macaluso A., McCoy D., Carnes K., Biltz J., Catania A. Antiinflammatory effects of the neuropeptide α -MSH in acute, chronic, and systemic inflammation. Ann. NY Acad. Sci. 741:1994;137-148.
20. Lundberg J. O., Hellstrom P. M., Lundberg J. M., Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet. 344:1994;1673-1674.
21. Macaluso A., McCoy D., Ceriani G., Watanabe T., Biltz J., Catania A., Lipton J. M. Antiinflammatory influences of α -MSH molecules: Central neurogenic and peripheral actions. J. Neurosci. 14:1994;2377-2382.
22. Murata Y., Ishiguro J., Munakata A., Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J. Gastroenterol. 30:((Suppl 8)):1995;56-60.
23. Murch S. H., Braegger C. P., Walker-Smith J. A., MacDonald T. T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 34:1993;1705-1709.
24. Olson A. D., DelBuono E. A., Bitar K. N., Remick D. G. Antiserum to tumor necrosis factor and failure to prevent murine colitis. J. Pediat. Gastroenterol. Nutr. 21:1995;410-418.
25. Powrie F., Leach M. W., Mauze S., Menon S., Caddle L. B., Coffman R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1:1994;553-562.
26. Rachmilewitz D., Karmeli F., Okon E. Sulfhydryl blocker-induced colonic inflammation is ameliorated by inhibition of nitric oxide synthase. Gastroenterology. 109:1995;98-106.
27. Rachmilewitz D., Stamler J. S., Bachwich D., Karmeli F., Ackerman Z., Podolsky D. K. Enhanced colonic nitric oxide generation and nitric oxide synthase in ulcerative colitis and Crohn's disease. Gut. 36:1995;718-723.
28. Rajora N., Ceriani G., Catania A., Star R. A., Murphy M. T., Lipton J. M. α -MSH production, receptors, and influence on neopterin, in a human monocyte/macrophage cell line. J. Leukocyte Biol. 59:1996;248-253.
29. Star R. A., Rajora N., Huang J., Chavez R., Catania A., Lipton J. M. Evidence of autocrine modulation of macrophage nitric oxide synthase by α -MSH. Proc. Natl. Acad. Sci. (USA). 92:1995;8016-8020.
30. Stevens, C.; Walz, G.; Singaram, C.; Lipman, M. L.; Zanker, B.; Muggia, A.; Antonioli, D.; Peppercorn, M. A.; Strom, T. B. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig. Dis. Sci. 37:8180-8126; 1992.
31. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody. Gastroenterology. 109:1995;129-135.
32. Woywodt A., Neustock P., Kruse A., Schwarting K., Ludwig D., Strange E. F., Kirchner H. Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. Eur. Cytokine Network. 5:1994;387-395.